methadone and carbamazepine

Carbamazepine is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2B6, which are major pathways for methadone metabolism. Induction increases the clearance of methadone, leading to reduced plasma concentrations.

Reduced methadone exposure may precipitate opioid withdrawal symptoms such as abdominal cramps, diarrhoea, piloerection, and flu-like symptoms. This can lead to treatment failure, increased craving, and relapse in patients on opioid substitution therapy. There is also a theoretical risk of QT prolongation if methadone doses are increased without proper monitoring.

Monitor closely for signs of opioid withdrawal, especially when starting or stopping carbamazepine. Consider increasing the methadone dose as needed, guided by clinical response and therapeutic drug monitoring of methadone concentrations. Adjust the methadone dose when carbamazepine is discontinued to avoid toxicity. Consider alternatives to carbamazepine where possible, or use caution with ECG monitoring if QT prolongation risk is high.

This interaction is well established and documented in clinical literature and drug interaction databases. It is based on pharmacokinetic studies and numerous clinical reports. Consistency across sources supports a clinically relevant effect.